-
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal serum retinol-binding protein-4 at 11-13weeks' gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013;62:814-9. -
Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: a case-control study.
Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH.
J Hum Hypertens 2013;27:38-43. -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Platelet changes and subsequent development of pre-eclampsia and fetal growth restriction in women with abnormal uterine artery Doppler screening.
Missfelder-Lobos H, Teran E, Lees C, Albaiges G, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;19:443-8. -
Vasoactive mediator release by fetal endothelial cells in intrauterine growth restriction and preeclampsia.
Parra MC, Lees C, Mann GE, Pearson JD, Nicolaides KH.
Am J Obstet Gynecol 2001;184:497-502.